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Objective: To investigate the efﬁcacy and toxicity of immunomodulatory therapy (IMT) alone or as an
add-on to palliative/salvage chemotherapy in patients with refractory/recurrent epithelial ovarian cancer
(EOC).
Materials and methods: We retrospectively analyzed the efﬁcacy and toxicity of IMT in 15 patients with
refractory/recurrent EOC who had previously received multiple chemotherapy regimens.
Results: The median age of the patients was 56 years (range, 41e75 years). Three patients were
platinum-sensitive, two were platinum-resistant, and the remaining 10 patients were refractory to
platinum-based front-line chemotherapy. IMT consisted of picibanil (OK-432) on Day 1, interleukin-2
and/or interferon-a on Day 2 administered by subcutaneous injection (every week or 2-weekly). Five
patients never received metronomic oral cyclophosphamide. After IMT, three patients achieved partial
remission (PR, lasting for 11 months,  12 months, and 16 months), and six patients had stable disease
(SD). The disease stabilizing rate (PRþSD) was 60% (3/3 in platinum-sensitive and 6/12 in platinum-
resistant/refractory patients). The absolute lymphocyte count (ALC) at 1 month after IMT was signiﬁ-
cantly higher in the PRþSD group (median 1242.0/mL) than in the progression group (median 325.0/mL)
(p ¼ 0.012). No  Grade 3 toxicities were observed. The median post-IMT survival time was 12 months
(range, 2e39 months).
Conclusion: IMT alone or add-on to palliative/salvage chemotherapy for refractory/recurrent EOC ach-
ieves a substantial disease stabilizing rate without severe toxicity, which might be a potential option in
selected patients. The ALC 1 month after IMT could be an early indicator to disease stabilization.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Epithelial ovarian cancer (EOC) is the eighth most common
malignancy and the seventh leading cause of cancer-related mor-
tality in womenworldwide [1]. In 2009, EOC accounts for 1113 new
cases, 438 deaths, and ranks the second lethal gynecologic malig-
nancy in Taiwan [2]. Although EOC is generally diagnosed at an
advanced stage, primary cytoreductive surgery followed by
platinum-based chemotherapy can ensure the achievement of a
complete remission (CR) in 70e80% of patients. Unfortunately,
60e70% of advanced EOC patients will have disease relapse afternd Gynecology, Chang Gung
an 333, Taiwan.
bstetrics & Gynecology. Publishedprimary treatment [3e5]. Furthermore, disease progression during
ﬁrst-line treatment is associated with a dismal prognosis.
In general, the response rates of platinum-sensitive patients to
second-line chemotherapy are usually > 30%. Conversely,
platinum-resistant patients show response rates as low as 10e20%
[3,5,6]. In addition, current salvage strategies for patients with re-
fractory/recurrent EOC are not effective and rarely curative.
Therefore, novel therapy treatment strategies have been eagerly
awaited.
Previous studies demonstrated the clinical usefulness of
immunomodulatory therapy (IMT) in several solid malignancies,
including lung cancer, hepatocellular carcinoma, prostate cancer,
melanoma, and renal cell carcinoma [7]. Because EOC have
immunogenic properties [8], the potential usefulness of immuno-
logical approaches for the treatment of advanced EOC is attractingby Elsevier Taiwan LLC. All rights reserved.
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lymphocytes has been shown to predict survival in EOC patients,
suggesting the prognostic relevance of immune surveillance
mechanisms in the course of this malignancy [9]. Notably, the in-
crease of regulatory T (Treg)-cells in patients with EOC has been
associated with a reduced survival [10]. The efﬁcacy and low
toxicity of IMT has been observed [8,11,12]. These results prompt us
to apply similar approaches in advanced EOC with refractory/
recurrent disease.
Penicillin-killed Streptococcus pyogenes [OK-432; Toll-like re-
ceptor (TLR) 4 agonist] is administered subcutaneously to activate
skin Langerhans cells to enhance antigen presenting and upregu-
lation of CD25 expression. OK-432 can trigger dendritic cell (DC)
activation via the TLR 4eMD2 signal pathway, inducing DC matu-
ration and linking innate cells and adaptive immune cells in host
immunosurveillance [13]. The clinical usefulness of OK-432 for the
treatment of lymphangioma, gastric cancer, and lung cancer has
been extensively investigated in Japan [13]. Interleukin (IL)-2 can
restore the ability of the immune system to produce CD4þ T cells
and increase IL-2-induced CD4þ CD25þ (CD4þFOXP3þ) T cells,
which can in turn suppress Treg cells [14,15]. IL-2 has been
approved in the United States for treating metastatic renal cell
carcinoma and metastatic melanoma [16]. Interferons (IFNs) may
exhibit important antitumoral and antiangiogenetic effects and
induce apoptosis in malignant cells [7]. Type I IFNs (a/b) systemi-
cally activate natural killer (NK) cells and support the differentia-
tion, maturation, and migration of DCs [17]. A single administration
of cyclophosphamide was shown to deplete CD4þCD25þ T cells in
tumor-bearing animals, delay tumor growth, and cure rats bearing
established tumors when followed by an immunotherapy that has
no curative effect when administered alone [18].
We therefore hypothesized that cytokine-based therapy in
combination with oral metronomic chemotherapy (as a form of
IMT) for refractory/recurrent EOC may improve survival. The pur-
pose of this study is to review the efﬁcacy and toxicity obtained in
patients treated with IMT alone or add-on to palliative/salvage
chemotherapy after failure of front-line treatment in our hospital.
Patients and methods
Patients
This study was approved by the Institutional Review Board of
the Chang Gung Memorial Hospital, Taoyuan, Taiwan (100-
3902A3). We retrospectively reviewed the medical records of 15
patients with refractory/recurrent advanced EOC who were treated
with cytokine-based IMT between December 2004 and January
2013. Inclusion criteria were as follows: (1) age  75 years at the
time of diagnosis of ovarian cancer; (2) pathologically-conﬁrmed
EOC; (3) initial treatment with surgical cytoreduction and
platinum-based chemotherapy; (4) evidence of disease progression
during ﬁrst-line chemotherapy (refractory), or evidence of disease
recurrence within 6 months after an initial response to ﬁrst-line
chemotherapy (platinum-resistant), or disease recurrence > 6
months after an initial complete response to ﬁrst-line chemo-
therapy (platinum-sensitive) but failed salvage systemic chemo-
therapy; and (5) use of IMT either alone or as an add-on to
chemotherapy.
Immunomodulatory therapy
IMT was performed with the following drugs: OK-432 [5 Klini-
sche Einheit (KE, a unit of OK-432 dose)/vial, Picibanil; Chugai
Pharmaceutical Co., Ltd. Tokyo, Japan], IL-2 (18 MIU/vial, Alde-
sleukin; Chiron B.V., Amsterdam, The Netherlands), peginterferon(PEG-IFN)-a-2a (3 MIU/0.5 mL/syringe, Roferon-A; F. Hoffmann-La
Roche Ltd., Basel, Switzerland), or IFN-b-1b [0.3 mg (9.6 MIU)/
vial, Betaferon; Novartis Vaccines and Diagnostics, Inc., Emeryville,
California, USA]. All of the patients received IMT either with or
without metronomic chemotherapy at the physician's discretion.
IMT was administered in the hospital by subcutaneous injections.
The use of OK-432 and IL-2 has been introduced since December
2004, whereas the administration of IFNs started in September
2006. Patients started IMT with a single agent, and other drugs
were subsequently added in patients who did not show severe side
effects. After 2011, the IMT regimens evolved into one vial of OK-
432 on Day 1, one vial of IL-2, and/or one vial of IFN-a-2a on Day
2 (or Day 2 and Day 3) weekly or 2-weekly. Cytokine agents were
discontinued in patients who showed severe chemotherapy-
related leukopenia, infections, clinical signs of target organ failure
due to disease progression, or who refused to continue IMT.
Salvage/palliative chemotherapy was administered after IMT if
there was no neutropenia or thrombocytopenia against its use.
Metronomic chemotherapy consisted of oral cyclophosphamide
50 mg once per day after salvage/palliative chemotherapy until the
next course IMT.
Taiwan Food and Drug Administration approved the use of OK-
432 for the treatment of gastrointestinal cancer, head and neck
cancer, thyroid cancer, and lung cancer; IL-2 for metastatic renal
cell carcinoma and metastatic melanoma; PEG-IFN-a-2a for Kapo-
si's sarcoma, renal cell carcinoma, hairy cell leukemia, chronic
hepatitis B and C, chronic myeloid leukemia, cutaneous T cell
lymphoma, and non-Hodgkin's lymphoma [19]. All of the patients
were informed about the off-label use of IMT for the treatment of
EOC.
Clinical assessment
The patients were classiﬁed as sensitive, resistant, or refractory
to platinum-based therapy depending on the interval between the
initial response and the ﬁrst relapse [20]. Routine blood counts,
liver function tests, renal function test, and serum CA-125 levels
were serially assessed prior to IMT and at follow-up. Lymphocyte
subsets were determined on a Beckman Coulter's Epics XL-MCL™
Flow Cytometer and analyzed using the XL SYSTEM II™ software.
We evaluated tumor response [CR, partial remission (PR), stable
disease (SD), and progressive disease (PD)] according to medical
records, imaging studies by Response Evaluation Criteria in Solid
Tumors (RECIST) criteria [21], and the Rustin guidelines by mea-
surement of serum CA-125 [22,23]. Data on treatment toxicity were
extracted from clinical charts and graded according to the National
Cancer Institute Common Terminology Criteria for Adverse Events,
version 4.0 (CTCAE v 4.0).
Statistical analysis
In patients with refractory disease, overall survival (OS) was
calculated from the date of diagnosis to the date of death. In pa-
tients with recurrent disease, survival after recurrence (SAR) was
calculated from the date of ﬁrst recurrence to the date of death.
Post-IMT progression-free survival (PFS) and post-IMT survival
(PIS) were determined from the date of IMT administration to the
date of the subsequent recurrence or death. The disease stabilizing
rate was deﬁned by summing up the percentages of CR, PR, and SD
lasting for at least 6 months. Descriptive statistics were calculated
for all characteristics of the study patients. Survival curves (PFS, OS,
SAR, and PIS) were generated using the KaplaneMeier method.
Differences in median values between groups were analyzed with
the ManneWhitney U test for comparison of the two independent
groups and the Wilcoxon signed ranks test for comparison of the
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statistical software (version 19.0; IBM, Somers, NY, USA). Two-
tailed p < 0.05 were considered to be statistically signiﬁcant.
Results
Patients
The clinical characteristics of the 15 patients are summarized in
Table 1. All of the patients received platinum-based front-line
chemotherapy. The median age was 56 years (range, 41e75 years).
Three patients were platinum-sensitive to ﬁrst-line chemotherapy,
two were platinum-resistant, and the remaining 10 patients were
refractory to platinum-based front-line chemotherapy.
Treatment
The treatment schemes and the clinical outcomes are shown in
Table 2. Patients were treated with IMT as an add-on to salvage/
palliative chemotherapy, either with or without metronomic oral
cyclophosphamide. However, some patients received IMT alone
when the general conditions did not allow the use of chemotherapy
(e.g., in the presence of thrombocytopenia).
The salvage/palliative chemotherapy used in this study was
usually at low doses, including cisplatin 40e100 mg/m2 3-weekly,
paclitaxel 50e80mg/m2 2-weekly, oral etoposide alone 50mg/d for
14 days 3-weekly, cyclophosphamide 600e750 mg/m2 3-weekly,
oral melphalan alone 0.2 mg/kg for 5 days 4-weekly, topotecan
2.5e3.5 mg/m2 weekly, pegylated liposomal doxorubicin (Lipo-Table 1
Demographics and clinicopathological data of 15 patients with recurrent/refractory
ovarian cancer on front-line chemotherapy who received IMT.
Characteristic No. %
Age (y)
Mean ± SD 57.1 ± 10.6
Median (range) 56 (41e75)
Performance status (ECOG)
2 2 13.3
3 11 73.3
4 2 13.3
FIGO stage at diagnosis
IIIC 13 86.7
IV 2 13.3
Histology
Serous 7 46.7
Mucinous 2 13.3
Endometrioid 1 6.7
Undifferentiated 3 20.0
Mixed 2 13.3
Mixed serous/endometrioid 1 6.7
Mixed papillary serous/endometrioid/clear cell 1 6.7
Grade
1 3 20.0
2 2 13.3
3 10 66.7
Primary surgery
Suboptimal debulking surgery 13 86.7
Optimal debulking surgery 2 13.3
Response to front-line chemotherapy
Sensitive 3 20.0
Resistant 2 13.3
Refractory 10 66.7
No. of previous regimens of chemotherapya
Median (range) 2 (1e4)
Mean 2.6
ECOG ¼ Eastern Cooperative Oncology Group performance status;
FIGO ¼ International Federation of Gynecology and Obstetrics;
IMT ¼ immunomodulatory therapy; SD ¼ standard deviation.
a Includes primary treatment.Dox) 12-40 mg/m2, gemcitabine 650e800 mg/m2 or 5-FU
600e1000 mg/m2 monthly, as a single agent or doublets, occa-
sionally with bevacizumab 5 mg/kg (Table 2).
Outcomes
At the date of the last follow-up (June 15, 2013), 14 patients died
of their disease and only one patient (Case 3) was alive with their
disease. After IMT, three patients (Cases 3, 13, 14) achieved PR
(lasting for 11 months,  12 months, and 16 months, respectively),
six patients had SD, whereas the remaining six patients showed PD
(Table 2).
In the entire study cohort, the disease stabilizing rate (PRþSD)
was 60% [100% (3/3) in the platinum-sensitive group, and 50% (6/
12) in the platinum-resistant/refractory group, respectively]. The
median PIS time was 12 months (range, 2e39 months). The 1-year
PIS rate was 53.3% (Fig. 1). The mean SAR after the ﬁrst recurrence
was 38.8 ± 30.9 months for patients with recurrent disease (plat-
inum-sensitive patients, 57.3 months; platinum-resistant patients,
11 months). The mean OS for patients in the refractory group was
18.2 ± 11.1 months, and six patients had a survival longer than 12
months.
Immunocyte proﬁles
The data of immunocyte proﬁles in patients with PRþSD and PD
after IMT is compared in Table 3. White blood cells (WBCs) and
absolute lymphocyte counts (ALCs) at baseline were within the
normal range. Prior to IMT, there were no signiﬁcant differences in
ALC between the PRþSD and the PD groups (p ¼ 0.529). After 1
month of IMT, the median values of WBC (p ¼ 0.027) and ALC
(p ¼ 0.012) were signiﬁcantly higher in the PRþSD group than in
the PD group. Although the median values of ALC in the PRþSD
group could be maintained at 1 month and 3 months after IMT, we
noted a signiﬁcant decline compared to the baseline values on the
verge of death (p ¼ 0.031). Both prior to and after IMT, there was a
trend towards higher median values of NK cells in the PRþSD group
compared with the PD group, although this difference was not
statistically signiﬁcant. In our series, the value of CD4/CD8 ratio did
not correlate with outcome.
Toxicity
In this study, all of the patients were hospitalized and were
given hydration therapy through an intravenous line both prior to
and during IMT. After the administration of OK-432, 11 patients
experienced Grade 2 fever (treated with acetaminophen) and one
patient showed Grade 1 fever. All of the 14 patients treated with IL-
2 had Grade 1/2 fever, but no cases of hypotension or arrhythmia
were observed. Two patients experienced pain and erythematous
changes (Grade 2) at the site of injection, whereas two other pa-
tients showed mild tenderness (Grade 1). No cases of renal or liver
impairment were noted.
Discussion
The prognosis of patients with refractory/recurrent EOC treated
by conventional salvage therapy is generally poor. Moreover, these
patients can experience severe adverse effects that may signiﬁ-
cantly impair the quality of life.
The clinical trials of single-agent chemotherapy (Lipo-Dox
[6,24e26], topotecan [6,27], gemcitabine [24], weekly paclitaxel
[28,29], and oral etoposide [30,31]) for refractory/resistant-
recurrent EOC have reported overall response rates of 6e35%,
median PFS of 2e6 months, and median OS of 5e20 months.
Table 2
Detailed treatment and outcome information of 15 patients with recurrent/refractory ovarian cancer on front-line chemotherapy who received IMT.
Patient
no.
Age
(y)
FIGO
stage
ECOGa/Platinum-free
interval
Prior treatment IMTc þ metronomic C/T Salvage/palliative systemic
C/Tb during IMT
Sites of Dx during IMT Response
to IMT
Post-IMT
PFSd (mo)
OS/SARe
(mo)
PISf
(mo)
Systemic C/Tb
(no. of regimens)
RT (sites) (No. of courses) (No. of courses)
Sensitive to 1st line C/T
1 45 IIIC 3/15 months CEKLPT (4) N/A OK-432 (12)
IL-2 (2)
OK-432þIL-2 (2)
oral Y (1)
KPCL (13) Pelvic tumor,
carcinomatosis
SD 15 50 18
2 60 IIIC 3/15 months CEKP (2) Yes (brain) OK-432 (8)
IFN b (1)
OK-432þIL-2 (8)
OK-432þIFN-a (7)
OK-432þ IFN-b (1)
IL-2þIFN-a (1)
OK-432þIL-2þIFN-a (4)
oral Y(2)
KPTFLYG (17) Brain, pelvic tumor,
carcinomatosis
SD 14 85 39
3 48 IIIC 2/10 months CKPLT (3) N/A OK-432 (3)
OK-432þIL-2 (3)
OK-432þIL-2þIFN-a (17)
oral Y (18)
P (14) Distal colon mass,
carcinomatosis
PR 12þ 37þ 12þ
Resistant to 1st line C/T
4 54 IIIC 2/5 months KP (1) Yes (pelvis) OK-432 (2)
IL-2 (1)
MP (2) Liver, spine,
carcinomatosis
SD 10 12 11
5 56 IIIC 3/5 months CKPY (2) Yes (subphrenic
and subumbilical
mass)
OK-432 (4)
OK-432þIL-2 (1)
OK-432þIFN-a (1)
oral Y (2)
CP (3) Pelvic tumor,
carcinomatosis
PD N/A 10 5
Refractory to 1st line C/T
6 49 IIIC 4/NA CKMPY (4) N/A OK-432 (2)
IL-2 (1)
MP (3) Pancreas,
carcinomatosis
PD N/A 8 2
7 75 IIIC 3/NA CPY(2) N/A OK-432 (3)
IL-2 (1)
OK-432þIL-2 (2)
OK-432þIFN-a (2)
oral Y (3)
CYP (4) Lung, MLN PD N/A 8 6
8 47 IIIC 3/NA CPY(2) Yes (PALN, lung) OK-432 (3)
OK-432þIL-2 (3)
oral Y (1)
CDPY (3) Lung, liver, PALN PD N/A 8 6
9 71 IIIC 4/NA CKP(2) Yes (pelvis) OK-432 (9)
OK-432þIL-2 (2)
CPEM (4) Liver, PALN,
carcinomatosis
SD 6 25 11
10 52 IIIC 3/NA CKLPY (4) N/A OK-432 (3)
IL-2 (3)
OK-432þIL-2 (5)
oral Y (2)
KDGFP (8) Breast,
carcinomatosis
PD N/A 18 17
11 69 IIIC 3/NA CY (1) N/A OK-432 (5) CYKP (3) Bone,
carcinomatosis
PD N/A 8 7
12 58 IIIC 3/NA CKPY (3) N/A OK-432 (5)
IL-2 (1)
OK-432þIL-2 (1)
OK-432þ IFN-a (1)
oral Y (1)
CKPFLG (8) Liver,
carcinomatosis
SD 6 22 17
13 41 IV 3/NA CLPT (4) Yes (pelvis) OK-432 (3)
OK-432þIL-2 (2)
OK-432þIL-2þIFN-a (1)
FKL (4) Pelvic tumor,
carcinomatosis
PR 11 41 13
C.-Y.Chen
et
al./
Taiw
anese
Journal
of
O
bstetrics
&
G
ynecology
54
(2015)
143
e
149
146
14
71
IV
3/
N
A
C
K
P
(2
)
N
/A
O
K
-4
32
(1
3)
IL
-2
(2
)
O
K
-4
32
þI
L-
2
(7
)
O
K
-4
32
þI
FN
- a
(1
)
or
al
Y
(3
)
K
PT
L
(8
)
Pe
lv
ic
tu
m
or
,
ca
rc
in
om
at
os
is
PR
16
26
22
15
63
II
IC
3/
N
A
C
K
PY
(3
)
N
/A
O
K
-4
32
(4
)
IL
-2
(2
)
O
K
-4
32
þI
L-
2
(4
)
IL
-2
þI
FN
- a
(1
)
or
al
Y
(2
)
D
K
PL
(6
)
SL
N
,P
A
LN
,p
el
vi
c
tu
m
or
,c
ar
ci
n
om
at
os
is
SD
8
21
16
C
/T
¼
ch
em
ot
h
er
ap
y;
D
x
¼
d
is
ea
se
;F
IG
O
¼
In
te
rn
at
io
n
al
Fe
d
er
at
io
n
of
G
yn
ec
ol
og
y
an
d
O
bs
te
tr
ic
s;
M
LN
¼
m
ed
ia
st
in
al
ly
m
p
h
n
od
e;
N
/A
¼
n
ot
ap
p
lic
ab
le
;P
A
LN
¼
p
ar
a-
ao
rt
ic
ly
m
p
h
n
od
e;
PD
¼
p
ro
gr
es
si
ve
d
is
ea
se
;P
R
¼
p
ar
ti
al
re
m
is
si
on
;
R
T
¼
ra
d
io
th
er
ap
y;
SD
¼
st
ab
le
d
is
ea
se
;
SL
N
¼
su
p
ra
cl
av
ic
u
la
r
ly
m
p
h
n
od
e.
a
Ea
st
er
n
C
oo
p
er
at
iv
e
O
n
co
lo
gy
G
ro
u
p
(E
CO
G
)
p
er
fo
rm
an
ce
st
at
u
s
w
h
en
p
at
ie
n
ts
be
ga
n
to
re
ce
iv
e
IM
T.
b
In
cl
u
d
es
fr
on
t-
lin
e
tr
ea
tm
en
t:
C
¼
ci
sp
la
ti
n
;D
¼
d
ox
or
u
bi
ci
n
;E
¼
et
op
os
id
e;
F
¼
5-
FU
;G
¼
ge
m
ci
ta
bi
n
e;
K
¼
ca
rb
op
la
ti
n
;L
¼
lip
os
om
al
e
d
ox
or
u
bi
ci
n
;M
¼
m
el
p
h
al
an
;P
¼
p
ac
lit
ax
el
;T
¼
to
p
ot
ec
an
;Y
¼
cy
cl
op
h
os
p
h
am
id
e.
c
IF
N
¼
in
te
rf
er
on
;
IL
-2
¼
in
te
rl
eu
ki
n
-2
;
IM
T
¼
im
m
u
n
om
od
u
la
to
ry
th
er
ap
y;
O
K
-4
32
¼
p
ic
ib
an
il.
d
Po
st
-I
M
T
PF
S
¼
p
ro
gr
es
si
on
-f
re
e
su
rv
iv
al
;
d
eﬁ
n
ed
fr
om
th
e
ti
m
e
p
at
ie
n
ts
ac
ce
p
te
d
IM
T
to
n
ex
t
re
cu
rr
en
ce
or
p
ro
gr
es
si
on
,i
n
cl
u
d
in
g
ti
ss
u
e
p
ro
of
,i
m
ag
e
ﬁ
n
d
in
g,
d
ou
bl
in
g
in
C
A
-1
25
fr
om
th
e
u
p
p
er
lim
it
of
n
or
m
al
(p
at
ie
n
ts
w
it
h
el
ev
at
ed
C
A
-1
25
p
re
tr
ea
tm
en
t
an
d
n
or
m
al
iz
at
io
n
of
C
A
-1
25
)
or
d
ou
bl
in
g
in
C
A
-1
25
fr
om
th
e
n
ad
ir
(p
at
ie
n
ts
w
h
os
e
C
A
-1
25
n
ev
er
fe
ll
to
th
e
n
or
m
al
ra
n
ge
).
e
O
S
¼
ov
er
al
ls
u
rv
iv
al
,d
eﬁ
n
ed
as
d
ia
gn
os
ti
c
d
at
e
to
d
ea
th
or
la
st
fo
llo
w
ed
-u
p
d
at
e
fo
r
re
fr
ac
to
ry
gr
ou
p
;
SA
R
¼
su
rv
iv
al
af
te
r
re
cu
rr
en
ce
,d
eﬁ
n
ed
as
th
e
ﬁ
rs
t
re
cu
rr
en
t
d
at
e
to
ex
p
ir
ed
or
la
st
fo
llo
w
ed
-u
p
d
at
e
fo
r
re
cu
rr
en
t
gr
ou
p
.
f
PI
S
¼
p
os
t-
IM
T
su
rv
iv
al
;
d
eﬁ
n
ed
as
p
at
ie
n
ts
ac
ce
p
te
d
IM
T
to
d
ea
th
or
la
st
fo
llo
w
-u
p
d
at
e.
Figure 1. Survival of the 15 patients after immunomodulatory therapy (IMT).
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therapies may result in higher response rates (17e39%), the median
PFS (3.0e5.4 months) and median OS (12.618.6 months) were not
improved [29,32e34].
In the present study, the use of IMT alone or add-on to salvage/
palliative chemotherapy resulted in amedian PIS time of 12months
(range, 2e39 months). The mean SAR after the ﬁrst recurrence was
57.3 months in the platinum-sensitive group and 11 months in the
platinum-resistant group. In the refractory group, the mean OS was
18.2 ± 11.1 months, and six patients achieved a survival longer than
12 months. Our results are noteworthy because 13 of the 15 pa-
tients had an ECOG performance status 3, with a mean number of
previous regimens of 2.6 (Tables 1 and 2). By contrast, patients
enrolled in previous Phase II/III clinical trials had a better perfor-
mance status (ECOG or WHO performance status of 0e2) and
generally failed only one previous regimen [6,24e34].
OK-432 can directly inhibit RNA synthesis in tumor cells,
interact between the immune system and cancer cells, and may act
as an adjuvant agent by inducing several cytokines [e.g., IL-1, IL-2,
IL-6, IL-8, IL-12, IL-18, granulocyte colony stimulating factor (G-
CSF), granulocyte myelocyte (GM)-CSF, IFN-a, and IFN-g] [13]. IL-2
triggers chemokine receptor CXCR4 chemokine (C-X-C motif) re-
ceptor 4 expression on Treg cells, enables Treg cells migration to-
ward chemokine CXCL12 chemokine (C-X-C motif) ligand 12 in
tumor microenvironment, and may enforce Treg cell tumor accu-
mulation [15]. Our IMT formula was evolving from OK-432 to
combinationwith IL-2 and/or IFN-a. Unfortunately, the IMTwas not
used under a prospective study, and the patients were treated in a
palliative manner. Without a formal funding, we did not systemi-
cally check T-cell subpopulations initially; therefore, the correlation
of response cannot be evaluated. In our series, we observed that the
median of ALC (p ¼ 0.012) at 1 month after IMT was signiﬁcantly
higher in the PRþSD group than the PD group. It might be explained
that certain patients have a better response to IMT, which could
expand and maintain cytotoxic lymphocytes.
The main adverse effects of IMT include fatigue, ﬂu-like symp-
toms, fever, injection site reaction, and transient paradoxical
Table 3
Immunocyte proﬁles in patients with stable disease or partial response disease and progressive disease after IMT.
Parameter PRþSD PD pf
N Median (range) N Median (range) Between groups Change from baseline
PRþSD PD
Baselinea WBC (/mL) 9 5700 (2700e6600) 6 7100 (1200e22500) 0.456 NA NA
ALC (/mL) 9 1425.60 (683e1885) 6 1119.3 (209e2363) 0.529 NA NA
CD4/CD8 7 1.0 (0.8e2.6) 5 2.4 (0.8e5.9) 0.220 NA NA
NK (/mL) 6 263.4 (160.2e424.1) 5 60.8 (8.6e330.8) 0.329 NA NA
1 mo laterb WBC (/mL) 7 4500 (2700e20800) 4 2600 (1400e3500) 0.027 >0.999 0.125
ALC (/mL) 7 1242.0 (988.0e2152.8) 4 325.0 (99.9e1050) 0.012c 0.578 0.250
CD4/CD8 6 1.45 (1.2e2.7) 4 1.3 (0.7e1.8) 0.719 0.063 >0.99
NK (/mL) 6 277.3 (41.0e387.5) 4 62.6 (29.4e172.2) 0.067 0.875 0.500
3 mo laterd WBC (/mL) 5 2300 (1400e7100) 5 2900 (1300e8000) 0.690 0.125 0.188
ALC (/mL) 5 1232 (690e1491) 5 756.0 (302e985) 0.222 0.063 0.813
CD4/CD8 4 1.2 (0.4e2.0) 6 1.0 (0.8e3.5) 0.413 0.750 0.125
NK (/mL) 2 286.6 (207.2e365.9) 5 64.5 (37.3e139.9) 0.095 0.500 0.483
<1 mo prior to deathe WBC (/mL) 6 2850 (1200e5000) 6 4350 (1100e10100) 0.511 0.031 0.156
ALC (/mL) 6 394.5 (216e779) 6 238.0 (116e404) 0.132 0.031 0.156
CD4/CD8 5 1.2 (0.2e2.4) 6 1.5 (0.7e2.5) 0.351 0.500 0.313
NK (/mL) 5 106.9 (61.9e195.2) 6 50.7 (11.3e107.5) 0.052 0.250 0.483
ALC¼ absolute lymphocyte count; IMT¼ immunomodulatory therapy; N¼ number of patients; NA¼ not applicable; NK¼ natural killer cell count; PD¼ progression disease;
PRþSD ¼ partial response or stable disease; WBC ¼ white blood cell count.
a Baseline: data prior to the date of the ﬁrst course of IMT.
b 1 month later: data at 1 month after the date of ﬁrst IMT.
c Remained signiﬁcant after Bonferroni correction of multiple comparisons.
d 3 months later: data at 3 months after the date of ﬁrst IMT.
e <1 month before death: all except one of the PRþSD group had disease progression at that time.
f The p values between the groups PRþSD and PD are based on ManneWhitney U test, and the p values in comparisons of change from baseline are based on Wilcoxon
signed ranks test.
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istration or leukopenia after IL-2 treatment). Because OK-432
contains penicillin, the risk of an allergic type hypersensitivity re-
action cannot be excluded [13,35].
Several limitations with regards to this study merit consider-
ation. First, most patients accepted this approach only when they
showed a poor ECOG performance status. Second, the retrospective
nature of our study and the small sample size may limit the ability
to generalize our ﬁndings. Third, the characteristics of the patients
were heterogeneous. Finally, the agents used for IMTand the timing
of treatment were not uniform (Table 2).
In conclusion, despite the limitations of this study, we can still
observe that IMT alone or add-on to salvage/palliative chemo-
therapy may achieve a good disease stabilizing rate for refractory/
recurrent EOC without severe toxicity, and it may therefore be a
potential option in selected patients. We also observed that the ALC
1 month after IMT could be an early indicator of disease stabiliza-
tion. Future studies in larger sample sizes with exploratory
immunocyte subpopulation [e.g., an increase of CD4þ CD25þ
(CD4þFOXP3þ) T cells and/or NK cells, CXCR4 expression of Treg]
and cytokine proﬁles (such as ILs, G-CSF, GM-CSF, IFN-a, and IFN-g)
are needed to conﬁrm our ﬁndings.Conﬂicts of interest
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